Form 4: Recursion Pharmaceuticals Director Acquires Shares Through Compensation Policy

Director Zavain Dar acquired 1,907 shares of Recursion Pharmaceuticals Class A Common Stock on January 2, 2025, as part of the company's Outside Director Compensation Policy.

Summary

• Zavain Dar, a director at Recursion Pharmaceuticals, acquired 1,907 shares of Class A Common Stock on January 2, 2025.
• The shares were acquired as part of the company's Outside Director Compensation Policy.
• The acquisition did not involve a monetary transaction, with a price of $0 per share.
• Following the transaction, Mr. Dar directly owns 108,132 shares of Recursion Pharmaceuticals.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to positively. It indicates alignment of interests between management and shareholders.

Positives

• The acquisition of shares by a director demonstrates alignment of interests with shareholders.
• The use of a compensation policy for directors is a standard corporate practice.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies. It reflects standard corporate governance procedures.

Comparison to Industry Standards

• Director compensation through stock grants is a common practice among publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Many companies use similar compensation policies to align director interests with shareholder value.
• The number of shares granted is relatively small compared to the total outstanding shares, which is typical for director compensation.

Stakeholder Impact

• The share acquisition has a minor positive impact on shareholders by aligning director interests with company performance.

Key Dates

Keywords

Recursion Pharmaceuticals, Director, Share Acquisition, Compensation Policy, Form 4, RXRX, Insider Trading